Karuna Therapeutics Inc (DELISTED) (KRTX:DL)
329.83
0.00 (0.00%)
USD |
NASDAQ |
Mar 18, 16:00
Karuna Therapeutics Cash from Financing (TTM): 483.37M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 483.37M |
| September 30, 2023 | 468.89M |
| June 30, 2023 | 1.310B |
| March 31, 2023 | 1.297B |
| December 31, 2022 | 855.78M |
| September 30, 2022 | 854.14M |
| June 30, 2022 | 10.70M |
| March 31, 2022 | 8.009M |
| December 31, 2021 | 277.58M |
| September 30, 2021 | 275.37M |
| June 30, 2021 | 275.15M |
| Date | Value |
|---|---|
| March 31, 2021 | 273.96M |
| December 31, 2020 | 3.659M |
| September 30, 2020 | 236.34M |
| June 30, 2020 | 330.06M |
| March 31, 2020 | 329.30M |
| December 31, 2019 | 405.28M |
| September 30, 2019 | 173.76M |
| June 30, 2019 | 97.39M |
| March 31, 2019 | 101.08M |
| December 31, 2018 | 27.58M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
3.659M
Minimum
Dec 2020
1.310B
Maximum
Jun 2023
419.27M
Average
277.58M
Median
Dec 2021
Cash from Financing (TTM) Benchmarks
| Bristol-Myers Squibb Co | 8.278B |
| RayzeBio inc (DELISTED) | -- |
| Icosavax Inc (DELISTED) | 78.07M |
| Madrigal Pharmaceuticals Inc | 1.116B |
| Theseus Pharmaceuticals Inc (DELISTED) | 49.74M |